The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan
Table 3
Adverse events per 100 patient-days.
Preferred terma
Percent of patients with adverse eventsb
No. of events
Adverse events per 100 patient-days
Blood and lymphatic system disorder
Anemia
4.5
1
1.15
Increased blood pressure
4.5
1
0.22
Increased blood urea
4.5
1
0.46
Leukopenia
4.5
1
2.00
Cardiac disorders
Chest pain
9.1
2
0.81
Dyspnea
4.5
2
2.34
Gastrointestinal disorder
Gastrointestinal disorder
4.5
1
1.19
Oropharyngeal pain
4.5
1
6.67
General disorders and administration site conditions
Pyrexia
13.6
3
14.17
Infection and infestation
Bronchitis
4.5
1
0.60
Herpes zoster
4.5
1
12.50
Investigations
Decreased blood creatinine
4.5
1
0.25
Increased blood creatinine
4.5
1
0.46
Decreased hemoglobin
13.6
4
1.9
Nervous system disorder
Dizziness
4.5
1
1.79
Metabolism and nutrition disorders
Edema peripheral
4.5
1
0.99
Musculoskeletal and connective tissue disorder
Arthralgia
9.1
2
13.81
Renal and urinary disorder
Dysuria
4.5
1
1.01
Renal colic
4.5
1
0.24
Respiratory, thoracic, and mediastinal disorders
Productive cough
13.6
4
7.61
Rhinorrhea
4.5
1
6.67
Sputum discolored
4.5
1
0.40
Wheezing
4.5
1
0.40
Skin and subcutaneous tissue disorders
Alopecia
4.5
1
1.79
Total
63.6
35
0.61
aMedical Dictionary for Regulatory Activities, version 22.1. bPatients experiencing the same adverse event multiple times were counted every time for the corresponding preferred term.
